Welcome to our dedicated page for Immunome SEC filings (Ticker: IMNM), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Immunome, Inc. (IMNM) SEC filings page on Stock Titan provides direct access to the company’s U.S. Securities and Exchange Commission disclosures, including Form 8-K current reports and other registered offerings. These documents are central for understanding how a clinical-stage targeted oncology company like Immunome describes its pipeline, clinical data and capital raising activities to regulators and investors.
Immunome’s recent Form 8-K filings cover several important topics. One 8-K details positive topline results from the global pivotal Phase 3 RINGSIDE trial of varegacestat, the company’s investigational oral gamma secretase inhibitor for progressing desmoid tumors, including the primary endpoint in progression-free survival and key secondary endpoints. The same filing discusses safety findings and the company’s stated plan to submit a New Drug Application for varegacestat to the U.S. Food and Drug Administration.
Other 8-Ks address financial and capital markets events, such as a follow-on public offering of common stock under an effective shelf registration statement on Form S-3, including the number of shares, public offering price and underwriters. Additional current reports reference quarterly financial results, business updates, and the furnishing of investor presentations that describe Immunome’s pipeline, including IM-1021, IM-3050 and preclinical ADC programs built around the HC74 TOP1 inhibitor payload.
Through this page, users can review how Immunome characterizes the design and potential attributes of its HC74 payload, summarizes preclinical data, and outlines risks and forward-looking statements in its regulatory language. Stock Titan enhances access to these filings with AI-powered summaries that highlight key points from lengthy documents, helping readers quickly identify clinical milestones, financing terms, and strategic disclosures without manually parsing every section.
Immunome (IMNM) reported Q3 2025 results showing a net loss of $57.5 million as collaboration revenue dropped to zero after its AbbVie agreement terminated in July 2025. Operating expenses rose to $60.1 million, driven by research and development of $49.2 million and general and administrative of $10.9 million.
Cash and cash equivalents were $272.6 million at September 30, 2025, up from $143.4 million at year-end, reflecting a January 2025 public offering and sales under its at-the-market program. Total liabilities were $35.5 million and stockholders’ equity was $263.9 million. The company states its cash is sufficient to fund operations for at least 12 months from the filing date.
Year to date, net loss improved to $142.5 million from $212.7 million in 2024 as in‑process R&D charges subsided. In January 2025, Immunome issued 22,258,064 shares for net proceeds of $161.7 million. During Q3 2025 it sold 4,625,156 shares via ATM for gross proceeds of $45.9 million; $134.1 million capacity remained at quarter end. Common shares outstanding were 91,710,277 as of November 3, 2025. The pipeline advanced with a Phase 3 trial of varegacestat (topline data expected in the second half of 2025) and ongoing early-stage programs.
Immunome (IMNM) filed an 8-K announcing third-quarter results. The company reported its financial results for the quarter ended September 30, 2025 and provided a business update via a press release furnished as Exhibit 99.1.
The disclosure was made under Item 2.02 (Results of Operations and Financial Condition). The press release is furnished, not filed, which means it is not subject to Section 18 liabilities and is not incorporated into other SEC filings unless expressly referenced. The filing also lists the Inline XBRL cover page as Exhibit 104.
FMR LLC and Abigail P. Johnson report beneficial ownership of 13,056,709.11 shares of Immunome Inc. common stock, representing 15.0% of the class. The filing shows sole dispositive power over 13,056,709.11 shares and sole voting power of 13,054,983 shares for FMR LLC, with no shared voting or dispositive power reported. The statement notes that the holdings are held in the ordinary course of business and not for the purpose of changing control. A related position — Fidelity Growth Company Commingled Pool — holds 5,133,293 shares or 5.9%. The filing references an agreement in Exhibit 99 and incorporated powers of attorney for signature authority.
Insider transaction summary for Immunome, Inc. (IMNM): Reporting person Jack Higgins, identified as an officer with the title Chief Scientific Officer, reported transactions dated 09/10/2025. He acquired 22,000 common shares by exercise/transaction code M at a price of $1.35 per share, bringing his reported direct beneficial ownership in common stock to 40,729 shares. The filing also reports derivative holdings: an employee stock option with a conversion/exercise price of $1.35 exercisable beginning 06/23/2032 and, following the reported transactions, 151,840 derivative securities are shown as beneficially owned. Vesting terms state 25% vested on 05/01/2023 with the remainder vesting in 36 equal monthly installments.
Immunome, Inc. (IMNM) – Form 4 insider filing
Chief Technical Officer Philip Tsai was granted an employee stock option for 190,000 common shares on 29-Jul-2025 at an exercise price of $10.60. The options expire on 28-Jul-2035. No common shares were bought, sold or otherwise transferred in the filing; the entire award is reported as directly owned.
Vesting schedule: 25 % of the grant vests on 29-Jul-2026; the remaining 75 % vests in 36 equal monthly installments thereafter. Following this grant, Tsai beneficially owns 190,000 derivative securities (options) and no change to his non-derivative share count is disclosed.
The transaction is a routine equity incentive meant to align executive interests with shareholders. Dilution will only occur if the options are exercised at prices above $10.60.
Immunome Inc. (IMNM) filed a Form 4 for Chief Medical Officer Dr. Robert Lechleider, reporting the grant of 242,000 employee stock options on 07/29/2025. The options carry a $10.60 exercise price and expire on 07/28/2035. Vesting terms: 25 % on 07/29/2026, then monthly vesting of the remaining 75 % over 36 months, leading to full vesting by 07/29/2029. After the award, the CMO beneficially owns 242,000 derivative securities; no common-stock holdings or open-market trades were disclosed. The transaction is coded “A” (grant) and is held directly; no 10b5-1 plan was indicated. The filing represents standard incentive compensation with no immediate share dilution or cash impact for investors.